定量组织速度成像技术评价罗格列酮对心力衰竭大鼠的防治作用  

Effects of rosglitazone on left ventricular remodeling and dysfunction in rats with congesitive heart failure evaluated by quantitative tissue velocity imaging

作　　者：刘洪智[1] 高传玉[1] 雷健[2] 罗兵[2] 李佐民[2] 周军[2] 贺立群[2] 戚本玲[3] 曹林生[3] 

机构地区：[1]河南省人民医院心内科,郑州450003 [2]湖北省武汉市第一医院心内科 [3]华中科技大学同济医学院附属协和医院心内科

出　　处：《中原医刊》2007年第17期1-3,共3页Central Plains Medical Journal

基　　金：武汉市科技计划项目资金资助（200302）

摘　　要：目的利用定量组织速度成像技术评价过氧化酶体增殖物激活受体γ（PPARγ）配体罗格列酮（ROS）对实验性心力衰竭大鼠的防治作用。方法60只雄性Wistar大鼠分三组：①心力衰竭模型组（CHF,n=25）,阿霉素2.5 mg/kg,尾静脉注射,每周1次,连续10周;②心力衰竭模型＋罗格列酮治疗组（ROS,n=25）,ROS 3 mg/kg,每天1次,灌胃治疗;③正常对照组（CON,n=10）。12周时进行M型超声和定量组织速度成像技术及血流动力学检测,放射免疫法检测血浆肿瘤坏死因子-α、血管紧张素Ⅱ及醛固酮水平。结果ROS组较CHF组死亡率明显降低（分别为20%和40%,P〈0.01）。与CON组相比,CHF组大鼠左室舒张末期内径（LVEDD）及收缩末期内径（LVESD）增加,心功能明显下降,表现为左室短轴缩短率（FS）、二尖瓣环收缩期长轴方向峰值运动速度（Vs）、左室压最大上升速率（＋dp/dtmax）、左室内压最大下降速率（-dp/dtmax）明显降低,左室舒张末期压（LVEDP）升高（P〈0.01）;ROS组左室内径增加程度降低,心功能各项指标改善。CHF组血浆肿瘤坏死因子-α、血管紧张素Ⅱ及醛固酮水平较CON组升高（P〈0.01）,而ROS治疗组降低（P〈0.01）。结论定量组织速度成像技术可无创评价PPARγ配体罗格列酮逆转心力衰竭大鼠左室重构改善心功能的作用。Objective To investigate the effects of peroxisome proliferator - activated receptorγ （PPARγ） ligand rosglitazoneon left ventricular remodeling and dysfunction in rats with congesitive heart failure evaluated by quantitative tissue velocity imaging. Methods Sixty weight - matched adult male Wistar rats were randomly divided into 3 groups as follows ： ①the CHF group, in which 2.5 mg/kg of adriamycin （ADR） was weekly injected via a tail vein for 10 weeks （n =25） ; ②the ROS group, concomitant rosghtazone and ADR, in which ROS as a PPARγligand was administered by daily garage at a dose of 3 mg/（ kg · d） （n = 25 ） ;③the control group （n = 10 ）. Hemodynamics and echocardiographic measurements were obtained at 12 weeks after treatment. The plasma concentrations of TNF - α, Ang II and Aldsterone were determined by immunoradiometric assay. Results Mortality was significantly lower for ROS -treated rat than that in CHF group （20% versus 40% , P 〈0.01 ）. Compared to the control group, LV end- diastolicdiameter （LVEDD）, LV end systolic diameter （LVESD） and LV end- diastolicpressure（ LV- EDP） were significantly increased in CHF group（ all P 〈 0. 01 ）. FS, Vs, ＋ dp/dtmax and - dp/dtmax, indices of LV contractile function, were significantly reduced in CHF group （ all P 〈 0. 01 ）. LV cavity dilatation was significantly attenuated in CHF group given rosghtazone. Rosglitazone partially normalized LV contractile function, which was significantly reduced in CHF group. The plasma concentrations of TNF - α, Ang II and Aldsterone were higher in the CHF group than the control group （ P 〈 0.01 ）, which was decreased by rosglitazone treatment. Conclusion Pretreatment with PPARγligand rosglitazone could attenuate left ventricular remodeling and failure in a rat model of CHF evaluated by quantitative tissue velocity imaging.

关 键 词：定量组织速度成像技术 过氧化酶体增殖物激活受体γ 罗格列酮 阿霉素 心力衰竭 

分 类 号：R541[医药卫生—心血管疾病]